Loading…
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-101M | $-103M | $-95M | -49.8% | - | 30.1% |
| 2024 | $0M | $-78M | $-79M | $-73M | -27.3% | - | 70.5% |
| 2023 | $0M | $-39M | $-47M | $-38M | -61.9% | -100.0% | 539.5% |
| 2022 | $11M | $-7M | $-7M | $-8M | -11.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 10.80 | 0 | 0 | 0 |
| Operating Revenue | - | 10.80 | 0 | 0 | 0 |
| Cost Of Revenue | 4.93 | 6.18 | - | - | - |
| Gross Profit | 5.12 | 4.62 | - | - | - |
| Operating Expense | - | 12.01 | 40.94 | 66.80 | 113.56 |
| Research And Development | - | 2.58 | 21.31 | 41.64 | 84.22 |
| Selling General And Administration | - | 9.43 | 21.06 | 26.61 | 30.23 |
| Total Expenses | - | 18.19 | 40.94 | 66.80 | 113.56 |
| Operating Income | - | -7.39 | -40.94 | -66.80 | -113.56 |
| Total Operating Income As Reported | - | -7.39 | -40.94 | -90.89 | -113.56 |
| EBITDA | - | -7.14 | -39.04 | -78.07 | -100.80 |
| Normalized EBITDA | - | -7.14 | -39.04 | -53.98 | -100.80 |
| EBIT | - | -7.39 | -40.02 | -80.38 | -104.05 |
| Interest Income | - | 0.12 | 0.93 | 10.52 | 8.11 |
| Interest Expense | - | - | 0.08 | 0.05 | 0.38 |
| Net Interest Income | - | 0.12 | 0.85 | 10.47 | 7.74 |
| Other Non Operating Income Expenses | - | - | 0 | - | 1.40 |
| Other Income Expense | -0.01 | - | -0.02 | -24.10 | 1.40 |
| Interest Income Non Operating | - | 0.12 | 0.93 | 10.52 | 8.11 |
| Interest Expense Non Operating | - | - | 0.08 | 0.05 | 0.38 |
| Net Non Operating Interest Income Expense | - | 0.12 | 0.85 | 10.47 | 7.74 |
| Pretax Income | - | -7.27 | -40.11 | -80.43 | -104.43 |
| Tax Provision | - | - | -2.65 | -2.10 | -0.79 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -0.63 | 0 |
| Net Income Continuous Operations | - | -7.27 | -37.46 | -78.33 | -103.64 |
| Net Income From Continuing And Discontinued Operation | - | -7.27 | -46.51 | -79.28 | -103.12 |
| Net Income From Continuing Operation Net Minority Interest | - | -7.27 | -37.46 | -78.33 | -103.64 |
| Net Income | - | -7.27 | -46.51 | -79.28 | -103.12 |
| Net Income Common Stockholders | - | -7.27 | -46.51 | -79.28 | -103.12 |
| Net Income Including Noncontrolling Interests | - | -7.27 | -46.51 | -79.28 | -103.12 |
| Normalized Income | - | -7.27 | -37.46 | -54.87 | -103.64 |
| Diluted NI Availto Com Stockholders | - | -7.27 | -46.51 | -79.28 | -103.12 |
| Basic Average Shares | - | 14.20 | 26.76 | 64.42 | 73.81 |
| Diluted Average Shares | - | 14.20 | 26.76 | 64.42 | 73.81 |
| Reconciled Depreciation | - | 0.25 | 0.99 | 2.31 | 3.25 |
| Reconciled Cost Of Revenue | 4.93 | 6.18 | - | - | - |
| Total Unusual Items | - | 0 | 0 | -24.09 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -24.09 | 0 |
| Preferred Stock Dividends | 0 | - | - | - | - |
| Net Income Discontinuous Operations | - | - | -9.05 | -0.95 | 0.51 |
| Special Income Charges | - | 0 | 0 | -24.09 | 0 |
| Impairment Of Capital Assets | - | - | 0 | 24.06 | 0 |
| General And Administrative Expense | - | 6.67 | 21.06 | 26.61 | 30.23 |
| Other Gand A | - | 5.90 | 21.06 | 26.61 | 30.23 |
| Salaries And Wages | 0.25 | 0.76 | - | - | - |
| Gain On Sale Of Ppe | - | 0 | 0 | -0.03 | 0 |
| Other Operating Expenses | - | - | -1.43 | -1.45 | -0.88 |
| Selling And Marketing Expense | 2.39 | 2.76 | - | - | - |
| Earnings From Equity Interest | - | - | -0.02 | -0.01 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Perspective Therapeutics, Inc.this co. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV |
| - |
| - |
| - |
| - |
| - |
| $377M |
| -14.88 |
| 28.41 |
| -190.9% |
| -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Puma Biotechnology, Inc. | PBYI | $357M | 11.47 | 2.74 | 23.9% | 6.67 |
| Peer Median | - | -3.75 | 2.70 | -36.4% | -3.28 | |